Douglas Richman

Q: What Schools Are Affiliated With Douglas Richman

Douglas Richman is affiliated with the following schools: University of Amsterdam, University of Minnesota, San Diego State University, University of California, San Diego, University of California, Los Angeles, University of Edinburgh, Stanford University, United States Military Academy, Johns Hopkins University, University of North Carolina at Chapel Hill, University of California, San Francisco, Thomas Jefferson University, Harvard University

Douglas Richman's AcademicInfluence.com Rankings

Douglas Richman

Biology

#3389

World Rank

#5194

Historical Rank

#1380

USA Rank

Virology

#55

World Rank

#57

Historical Rank

#21

USA Rank

biology Degrees

Download Badge

Biology

Douglas Richman's Degrees

Doctorate Medicine University of California, San Francisco
PhD Virology University of California, San Francisco

Why Is Douglas Richman Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Douglas D. Richman is an American infectious diseases physician and medical virologist. Richman's work has focused on the HIV/AIDS pandemic, since its appearance in the early 1980s. His major contributions have been in the areas of treatment, drug resistance, and pathogenicity.

(See a Problem?)

Douglas Richman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. (1997) (2876)
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. (1987) (2759)
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. (2008) (2385)
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. (1997) (2126)
Update of the Drug Resistance Mutations in HIV-1. (2008) (2026)
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. (1997) (1911)
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections (2002) (1736)
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. (1989) (1515)
The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. (1987) (1503)
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. (1997) (1316)
Rapid evolution of the neutralizing antibody response to HIV type 1 infection (2003) (1280)
The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation (2010) (1129)
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. (2000) (1117)
Antiretroviral Treatment of Adult HIV Infection (2008) (1090)
HIV-Specific Cd8+ T Cells Produce Antiviral Cytokines but Are Impaired in Cytolytic Function (2000) (1010)
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. (1998) (1006)
Antiretroviral-drug resistance among patients recently infected with HIV. (2002) (993)
Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants (1997) (979)
Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. (1999) (966)
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. (2000) (917)
The Challenge of Finding a Cure for HIV Infection (2009) (879)
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. (2008) (828)
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. (2002) (777)
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. (2006) (769)
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. (2012) (742)
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. (2004) (730)
Antiretroviral therapy for HIV infection in 1996 : Recommendations of an international panel (1996) (651)
Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome (2004) (617)
A Health Status Questionnaire Using 30 Items From The Medical Outcomes Study: Preliminary Validation in Persons With Early HIV Infection (1991) (597)
Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy (1994) (596)
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. (1998) (593)
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. (2003) (575)
Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections. Studies with neuropsychologic testing and magnetic resonance imaging. (1987) (570)
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. (2008) (569)
Extensive polymorphisms observed in HIV–1 clade B protease gene using high–density oligonucleotide arrays (1996) (559)
Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. (1992) (546)
Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies (2013) (537)
Absence of detectable HIV-1 viremia after treatment cessation in an infant. (2013) (536)
Defective proviruses rapidly accumulate during acute HIV-1 infection (2016) (534)
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection a double-blind, placebo-controlled trial (1990) (532)
Immune Activation and CD8+ T-Cell Differentiation towards Senescence in HIV-1 Infection (2004) (463)
Apoptosis as a mechanism of cell death in cultured T lymphoblasts acutely infected with HIV-1. (1991) (456)
Highly Precise Measurement of HIV DNA by Droplet Digital PCR (2013) (454)
Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication. (1990) (454)
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. (1996) (451)
The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. (1994) (440)
The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes (1994) (433)
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study (2005) (420)
The prevalence of antiretroviral drug resistance in the United States (2004) (419)
Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene (1994) (402)
Prevalence and predictive value of intermittent viremia with combination hiv therapy. (2001) (395)
Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. (2005) (373)
International AIDS Society global scientific strategy: towards an HIV cure 2016 (2016) (372)
Prevalence of psychiatric disorders among men infected with human immunodeficiency virus. A controlled study. (1988) (370)
Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C (2008) (369)
Reduced antiretroviral drug susceptibility among patients with primary HIV infection. (1999) (367)
Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. (1991) (356)
A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. (1992) (340)
2011 update of the drug resistance mutations in HIV-1. (2011) (339)
Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. (2013) (330)
Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. (2000) (329)
Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. (2000) (317)
Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. (1998) (316)
Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. (1993) (316)
Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest (1995) (313)
Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. (2005) (312)
Viral Dynamics of Acute HIV-1 Infection (1999) (303)
A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome (1990) (303)
HIV chemotherapy (2001) (294)
In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues (1997) (293)
Interferons and bacterial lipopolysaccharide protect macrophages from productive infection by human immunodeficiency virus in vitro (1989) (291)
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs (2013) (288)
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. (2004) (283)
Drug resistance mutations in HIV-1. (2003) (280)
Evidence for Increased T Cell Turnover and Decreased Thymic Output in HIV Infection1 (2001) (280)
Challenges in Detecting HIV Persistence during Potentially Curative Interventions: A Study of the Berlin Patient (2013) (275)
A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. (2002) (274)
Zidovudine treatment of the AIDS dementia complex: Results of a placebo‐controlled trial (1993) (274)
HIV chemotherapy : AIDS (2001) (267)
A new reporter cell line to monitor HIV infection and drug susceptibility in vitro. (1997) (260)
Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: Intrinsic stability predicts lifelong persistence (2003) (259)
Zidovudine Resistance and HIV-1 Disease Progression during Antiretroviral Therapy (1995) (257)
Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. (1998) (255)
Update of the drug resistance mutations in HIV-1: Fall 2005. (2005) (254)
Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. (1998) (252)
Nomenclature for antiviral‐resistant human hepatitis B virus mutations in the polymerase region (2001) (251)
Update of the drug resistance mutations in HIV-1: Fall 2006. (2006) (250)
Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. (1997) (248)
Predictors of Self‐Reported Adherence and Plasma HIV Concentrations in Patients on Multidrug Antiretroviral Regimens (2000) (248)
Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure. (1996) (247)
Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. (2008) (244)
Update of the drug resistance mutations in HIV-1: March 2013. (2013) (237)
Update of the drug resistance mutations in HIV-1: December 2010. (2010) (234)
Adaptation to Different Human Populations by HIV-1 Revealed by Codon-Based Analyses (2006) (232)
Update of the drug resistance mutations in HIV-1: December 2009. (2008) (231)
HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat. (2014) (229)
A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals (2015) (228)
Antiretroviral resistance during successful therapy of HIV type 1 infection. (2000) (226)
Persistence of Transmitted Drug Resistance among Subjects with Primary Human Immunodeficiency Virus Infection (2008) (226)
Evolution of Envelope Sequences of Human Immunodeficiency Virus Type 1 in Cellular Reservoirs in the Setting of Potent Antiviral Therapy (1999) (221)
Producer-cell modification of human immunodeficiency virus type 1: Nef is a virion protein (1996) (217)
Human Immunodeficiency Virus Replication and Genotypic Resistance in Blood and Lymph Nodes after a Year of Potent Antiretroviral Therapy (1998) (217)
Diagnosis of Primary HIV-1 Infection (2001) (216)
Viral Dynamics of HIV: Implications for Drug Development and Therapeutic Strategies (1996) (215)
Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents (1993) (215)
Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro (1995) (213)
HIV persistence in tissue macrophages of humanized myeloid only mice during antiretroviral therapy (2017) (212)
Inhibition of HIV replication in acute and chronic infections in vitro by a Tat antagonist. (1991) (211)
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. (2000) (207)
Preferential replication of HIV-1 in the CD45RO memory cell subset of primary CD4 lymphocytes in vitro. (1997) (205)
Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. (1990) (205)
The global transmission network of HIV-1. (2014) (205)
Dissecting the Neutralizing Antibody Specificities of Broadly Neutralizing Sera from Human Immunodeficiency Virus Type 1-Infected Donors (2007) (204)
Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients (1996) (204)
Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay (1990) (202)
Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Variation and Neutralizing Antibody Responses during Transmission of HIV-1 Subtype B (2005) (201)
Inhibition of HIV replication by pokeweed antiviral protein targeted to CD4+ cells by monoclonal antibodies (1990) (189)
Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. (2001) (188)
A pilot study of low-dose zidovudine in human immunodeficiency virus infection. (1990) (184)
Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study. (2020) (183)
Update of the drug resistance mutations in HIV-1: 2007. (2007) (183)
The binding of staphylococcal protein A by the sera of different animal species. (1982) (181)
Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. (1996) (181)
2017 Update of the Drug Resistance Mutations in HIV-1. (2016) (177)
Thymidine kinase obliteration: creation of transgenic mice with controlled immune deficiency. (1989) (177)
Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. (2013) (177)
Treatment of Recurrent Genital Herpes Simplex Infections With Oral Acyclovir: A Controlled Trial (1984) (174)
HIV superinfection. (2005) (174)
Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. (2003) (174)
HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study (2017) (171)
Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. (1992) (165)
Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. (2011) (164)
Localization of human cytomegalovirus in peripheral blood leukocytes by in situ hybridization. (1990) (161)
Update of the Drug Resistance Mutations in HIV-1: 2005. (2005) (160)
Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection. (1984) (160)
BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine (1991) (157)
Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. (1998) (156)
Rapid accumulation of human immunodeficiency virus (HIV) in lymphatic tissue reservoirs during acute and early HIV infection: implications for timing of antiretroviral therapy. (2000) (154)
Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. (2008) (151)
The growth advantage conferred by HIV-1 nef is determined at the level of viral DNA formation and is independent of CD4 downregulation. (1995) (150)
Prevalence and Clinical Significance of Zidovudine Resistance Mutations in Human Immunodeficiency Virus Isolated from Patients after Long-Term Zidovudine Treatment (1995) (148)
2014 Update of the drug resistance mutations in HIV-1. (2014) (146)
Genetic Composition of Human Immunodeficiency Virus Type 1 in Cerebrospinal Fluid and Blood without Treatment and during Failing Antiretroviral Therapy (2005) (146)
Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society–USA Panel (2018) (146)
Mechanisms for the Inhibition of HIV Replication by Interferons-α, -β, and -γ, in Primary Human Macrophages (1993) (146)
Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. (2001) (145)
Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. (2000) (145)
Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy (2000) (145)
2019 update of the drug resistance mutations in HIV-1. (2019) (142)
Update of the drug resistance mutations in HIV-1: Spring 2008. (2008) (142)
2015 Update of the Drug Resistance Mutations in HIV-1. (2015) (140)
Productive infection of T cells in lymphoid tissues during primary and early human immunodeficiency virus infection. (2001) (140)
Whither or Wither Microbicides? (2008) (139)
A new perspective on V3 phenotype prediction. (2003) (138)
Clade B HIV-1 superinfection with wild-type virus after primary infection with drug-resistant clade B virus (2003) (138)
Rates of Emergence of HIV Drug Resistance in Resource-Limited Settings: A Systematic Review (2012) (135)
CD40 ligand (CD154) stimulation of macrophages to produce HIV-1-suppressive beta-chemokines. (1998) (135)
A Sound Rationale Needed for Phase III HIV-1 Vaccine Trials (2004) (133)
Persistent Cryptococcus neoformans infection of the prostate after successful treatment of meningitis. California Collaborative Treatment Group. (1989) (130)
HIV-specific Cytotoxic T Cells from Long-Term Survivors Select a Unique T Cell Receptor (2004) (129)
Incidence of HIV superinfection following primary infection. (2004) (128)
CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1–infected individuals (2008) (128)
Failure of dideoxynucleosides to inhibit human immunodeficiency virus replication in cultured human macrophages (1987) (127)
Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. (2000) (125)
HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment. (2014) (125)
Quality of life in a placebo-controlled trial of zidovudine in patients with AIDS and AIDS-related complex. (1990) (122)
Gut Lactobacillales are associated with higher CD4 and less microbial translocation during HIV infection (2013) (121)
T cell recognition of HIV synthetic peptides in a natural infection. (1989) (117)
Immunostimulatory DNA-Based Vaccines Elicit Multifaceted Immune Responses Against HIV at Systemic and Mucosal Sites1 (2001) (117)
Report of the NIH Panel To Define Principles of Therapy of HIV Infection* (1998) (117)
Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. (2006) (116)
Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2',3'-dideoxyadenosine derivatives. (1988) (115)
Antiviral drug resistance. (2006) (115)
Drug Resistance Patterns, Genetic Subtypes, Clinical Features, and Risk Factors in Military Personnel with HIV-1 Seroconversion (1999) (115)
HIV drug resistance acquired through superinfection (2005) (115)
HIV-1: Gambling on the evolution of drug resistance? (1997) (114)
Temporal gene regulation during HIV-1 infection of human CD4+ T cells. (2001) (114)
Reinfection results in accumulation of unintegrated viral DNA in cytopathic and persistent human immunodeficiency virus type 1 infection of CEM cells (1990) (114)
Alternative splice acceptor utilization during human immunodeficiency virus type 1 infection of cultured cells (1990) (112)
A public health model for the molecular surveillance of HIV transmission in San Diego, California (2009) (112)
HIV induces lymphocyte apoptosis by a p53‐initiated, mitochondrial‐mediated mechanism (2001) (111)
Semen-Specific Genetic Characteristics of Human Immunodeficiency Virus Type 1 env (2005) (111)
Update of the drug resistance mutations in HIV-1: 2004. (2004) (110)
Drug resistance mutations in HIV-1. (2003) (108)
Incidence and impact of resistance against approved antiretroviral drugs (2000) (106)
Genetic attributes of cerebrospinal fluid-derived HIV-1 env. (2006) (105)
Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy (2000) (103)
Rapid viral diagnosis. (1984) (103)
Non-Hodgkin's lymphoma in patients with advanced HIV infection treated with zidovudine. (1991) (101)
Antibodies to Epstein-Barr virus-determined antigens in normal subjects and in patients with seropositive rheumatoid arthritis. (1979) (101)
Detection of Minority Resistance during Early HIV-1 Infection: Natural Variation and Spurious Detection rather than Transmission and Evolution of Multiple Viral Variants (2011) (100)
Temperature-sensitive mutants of influenza virus. VI. Transfer of TS lesions from the Asian subtype of influenza A virus (H2N2) to the Hong Kong subtype (H3N2). (1975) (99)
Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. (2000) (99)
Identification of a new glycoprotein of herpes simplex virus type 1 and genetic mapping of the gene that codes for it (1986) (97)
Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates. (1994) (97)
In vivo antagonism with zidovudine plus stavudine combination therapy. (2000) (97)
A cross-sectional comparison of persons with syncytium- and non-syncytium-inducing human immunodeficiency virus. (1993) (97)
Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy (1996) (96)
CD4+ and CD8+ T Cell Activation Are Associated with HIV DNA in Resting CD4+ T Cells (2014) (96)
The role of interferons in the control of HIV replication in macrophages. (1990) (96)
Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network. (2001) (96)
The Origins of Sexually Transmitted HIV Among Men Who Have Sex with Men (2010) (95)
Synthesis and antiretroviral activity of phospholipid analogs of azidothymidine and other antiviral nucleosides. (1990) (94)
The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis (2002) (93)
Human Immunodeficiency Virus Type 1 Clade B Superinfection: Evidence for Differential Immune Containment of Distinct Clade B Strains (2005) (92)
Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescents. (2014) (90)
Racial and Ethnic Differences in Outcome in Zidovudine-Treated Patients With Advanced HIV Disease (1991) (90)
Dynamics of T Cell Responses in HIV Infection1 (2002) (89)
CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells (2018) (89)
Conjugation of protein to immunostimulatory DNA results in a rapid, long‐lasting and potent induction of cell‐mediated and humoral immunity (2000) (89)
Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group. (1989) (89)
The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B (2000) (88)
Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis (2000) (88)
Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication. (1990) (88)
MULTIPLE MEASURES OF HIV BURDEN IN BLOOD AND TISSUE ARE CORRELATED WITH EACH OTHER BUT NOT WITH CLINICAL PARAMETERS IN AVIREMIC SUBJECTS (2002) (87)
Spatiotemporal dynamics of HIV propagation. (2002) (87)
2-LTR circular viral DNA as a marker for human immunodeficiency virus type 1 infection in vivo. (1994) (86)
Minority variants of drug-resistant HIV. (2010) (85)
Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study. (2017) (85)
Resting cerebral blood flow (2009) (84)
Human APOBEC3 Induced Mutation of Human Immunodeficiency Virus Type-1 Contributes to Adaptation and Evolution in Natural Infection (2014) (84)
Acquired immunodeficiency syndrome. Magnetic resonance patterns of brain involvement with pathologic correlation. (1988) (84)
Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors: A Clinical Review of Antiretroviral Resistance (2002) (78)
The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection. (2000) (78)
Mechanisms for the inhibition of HIV replication by interferons-alpha, -beta, and -gamma in primary human macrophages. (1993) (77)
The antiviral effect of zidovudine and ribavirin in clinical trials and the use of p24 antigen levels as a virologic marker. (1989) (77)
Nucleic acid amplification in vitro: detection of sequences with low copy numbers and application to diagnosis of human immunodeficiency virus type 1 infection (1989) (77)
Simian Immunodeficiency Virus Engrafted with Human Immunodeficiency Virus Type 1 (HIV-1)-Specific Epitopes: Replication, Neutralization, and Survey of HIV-1-Positive Plasma (2006) (77)
Reversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV-1 infection. (1999) (76)
Reduced Susceptibility of Human Immunodeficiency Virus Type 1 (HIV-1) from Patients with Primary HIV Infection to Nonnucleoside Reverse Transcriptase Inhibitors Is Associated with Variation at Novel Amino Acid Sites (2000) (76)
HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing (2015) (75)
Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: implications for secondary transmission. (2007) (75)
Phylogenetic analysis of population-based and deep sequencing data to identify coevolving sites in the nef gene of HIV-1. (2010) (75)
Recommendations for measuring HIV reservoir size in cure-directed clinical trials (2020) (74)
Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression (2001) (73)
Shedding of HIV and human herpesviruses in the semen of effectively treated HIV-1-infected men who have sex with men. (2013) (73)
Human immunodeficiency virus infection of monoblastoid cells: cellular differentiation determines the pattern of virus replication (1988) (73)
Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals. (2015) (73)
Effects of Antiretroviral Drugs on Human Immunodeficiency Virus Type 1-Induced CD4+ T-Cell Death (2002) (72)
Associations between Virologic and Immunologic Dynamics in Blood and in the Male Genital Tract (2011) (72)
Dynamics of T Cell Responses in HIV Infection (2002) (72)
Measuring the latent reservoir in vivo. (2016) (71)
Evolution of the interferon alpha gene family in eutherian mammals. (2007) (70)
Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance. (2005) (69)
Use of self-sustained sequence replication amplification reaction to analyze and detect mutations in zidovudine-resistant human immunodeficiency virus. (1991) (69)
Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. (1999) (68)
Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine (2003) (68)
Polyclonal proliferation and apoptosis of CCR5+ T lymphocytes during primary human immunodeficiency virus type 1 infection: regulation by interleukin (IL)-2, IL-15, and Bcl-2. (2003) (68)
A Multi-Investigator/Institutional DNA Bank for AIDS-Related Human Genetic Studies: AACTG Protocol A5128 (2003) (68)
Antigen-specific antibody Fc glycosylation enhances humoral immunity via the recruitment of complement (2018) (67)
Impact of Pneumocystis carinii and cytomegalovirus on the course and outcome of atypical pneumonia in advanced human immunodeficiency virus disease. (1992) (67)
Interferon gene expression following HIV type 1 infection of monocyte-derived macrophages. (2004) (67)
Cytomegalovirus Replication in Semen Is Associated with Higher Levels of Proviral HIV DNA and CD4+ T Cell Activation during Antiretroviral Treatment (2014) (66)
Physicochemical properties of Marburg virus: evidence for three distinct virus strains and their relationship to Ebola virus. (1988) (66)
Antigenic analysis of strains of Ebola virus: identification of two Ebola virus serotypes. (1983) (66)
Human immunodeficiency virus-1 infection of macrophages in vitro neither induces tumor necrosis factor (TNF)/cachectin gene expression nor alters TNF/cachectin induction by lipopolysaccharide. (1990) (65)
Productive infection and subsequent interaction of CD4-gp120 at the cellular membrane is required for HIV-induced apoptosis of CD4+ T cells. (1995) (65)
HIV excretion patterns and specific antibody responses in body fluids (1990) (65)
A pilot study to evaluate the development of resistance to nevirapine in asymptomatic human immunodeficiency virus-infected patients with CD4 cell counts of > 500/mm3: AIDS Clinical Trials Group Protocol 208. (1995) (65)
The association of the temperature-sensitive phenotype with viral attenuation in animals and humans: implications for the development and use of live virus vaccines. (1979) (64)
Latently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation activity. (2009) (62)
HIV drug resistance. (1992) (62)
Detection of herpes simplex virus in clinical specimens by DNA hybridization. (1983) (61)
Immunologic and electrophysiological response to cytomegaloviral inner ear infection in the guinea pig. (1984) (61)
Hearing Loss in Experimental Cytomegalovirus Infection of the Guinea Pig Inner Ear: Prevention by Systemic Immunity (1985) (61)
Adaptation to Human Populations Is Revealed by Within-Host Polymorphisms in HIV-1 and Hepatitis C Virus (2007) (60)
Upregulation of BST-2/Tetherin by HIV Infection In Vivo (2011) (59)
Cytomegalovirus DNA in semen and blood is associated with higher levels of proviral HIV DNA. (2013) (58)
Zidovudine Compared With Didanosine in Patients With Advanced HIV Type I Infection and Little or No Previous Experience With Zidovudine (1995) (58)
Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors (2001) (58)
Susceptibility to nucleoside analogues of zidovudine-resistant isolates of human immunodeficiency virus. (1990) (57)
Antibody to a synthetic oligopeptide in subjects at risk for human immunodeficiency virus infection (1987) (57)
Herpes simplex virus 2 serostatus and viral loads of HIV-1 in blood and semen as risk factors for HIV transmission among men who have sex with men (2008) (55)
Antiproliferative effect of retinoid compounds on Kaposi's sarcoma cells. (1994) (55)
Racial and ethnic differences in outcome in zidovudine-treated patients with advanced HIV disease. Zidovudine Epidemiology Study Group. (1991) (55)
Kinetic analysis of intravirion reverse transcription in the blood plasma of human immunodeficiency virus type 1-infected individuals: direct assessment of resistance to reverse transcriptase inhibitors in vivo (1996) (54)
Evaluation of an HIV Nucleic Acid Testing Program With Automated Internet and Voicemail Systems to Deliver Results (2010) (54)
Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients (2000) (54)
Characterization and growth in human macrophages of Mycobacterium avium complex strains isolated from the blood of patients with acquired immunodeficiency syndrome (1990) (54)
Alternating and Intermittent Regimens of Zidovudine and Dideoxycytidine in Patients with AIDS or AIDS-Related Complex (1993) (54)
HIV-induced apoptosis requires the CD4 receptor cytoplasmic tail and is accelerated by interaction of CD4 with p56lck (1996) (53)
Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy. (2001) (53)
Characterization of genetic variation and 3'-azido-3'-deoxythymidine- resistance mutations of human immunodeficiency virus by the RNase A mismatch cleavage method. (1991) (52)
Replication of Human Herpesviruses Is Associated with Higher HIV DNA Levels during Antiretroviral Therapy Started at Early Phases of HIV Infection (2016) (52)
Characterization of HIV Isolates Arising After Prolonged Zidovudine Therapy (1992) (52)
Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. (1984) (52)
Psoralen inactivation of influenza and herpes simplex viruses and of virus-infected cells (1981) (52)
Congenital cytomegalovirus labyrinthitis and sensorineural hearing loss in guinea pigs. (1989) (52)
Incidence of AIDS dementia in a two-year follow-up of AIDS and ARC patients on an initial phase II AZT placebo-controlled study: San Diego cohort. (1992) (51)
Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. (2008) (51)
Studies of HIV infection and the development of Epstein-Barr virus-related B cell lymphomas following transfer of human lymphocytes to mice with severe combined immunodeficiency. (1989) (51)
Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus. (1994) (51)
Vaccine-Induced Immune Responses in Rodents and Nonhuman Primates by Use of a Humanized Human Immunodeficiency Virus Type 1 pol Gene (2002) (51)
Scarlet fever and group A streptococcal surgical wound infection traced to an anal carrier. (1977) (50)
Three strains of influenza A virus (H3N2): interferon sensitivity in vitro and interferon production in volunteers (1976) (50)
Zidovudine resistance of human immunodeficiency virus. (1990) (50)
Natural history of advanced HIV disease in patients treated with zidovudine. The Zidovudine Epidemiology Study Group. (1992) (50)
Influence of host cell type and V3 loop of the surface glycoprotein on susceptibility of human immunodeficiency virus type 1 to polyanion compounds (1994) (50)
The implications of drug resistance for strategies of combination antiviral chemotherapy. (1996) (50)
How to best measure HIV reservoirs? (2013) (49)
Results of continued monitoring of participants in the placebo-controlled trial of zidovudine for serious human immunodeficiency virus infection. (1988) (49)
Clinical utility of HIV standard genotyping among antiretroviral-naive individuals with unknown duration of infection. (2007) (49)
Temperature-sensitive mutants of influenza. VIII. Genetic and biological characterization of TS mutants of influenza virus A (H3N2) and their assignment to complementation groups. (1975) (48)
A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575 (2005) (48)
Probing chelation motifs in HIV integrase inhibitors (2012) (48)
Select host restriction factors are associated with HIV persistence during antiretroviral therapy (2015) (47)
HIV therapeutics : The new face of AIDS (1996) (47)
Extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy: A case study (2017) (47)
Reduced intracellular growth of mycobacteria in human macrophages cultivated at physiologic oxygen pressure. (1992) (47)
Stampidine Is a Potent Inhibitor of Zidovudine- and Nucleoside Analog Reverse Transcriptase Inhibitor-Resistant Primary Clinical Human Immunodeficiency Virus Type 1 Isolates with Thymidine Analog Mutations (2002) (46)
Pneumocystis Prophylaxis and Survival in Patients With Advanced Human Immunodeficiency Virus Infection Treated With Zidovudine (1992) (46)
Evidence for positive selection driving the evolution of HIV-1 env under potent antiviral therapy. (2001) (46)
Prevalence of Transmitted HIV Drug Resistance Among Recently Infected Persons in San Diego, CA 1996–2013 (2016) (46)
New assays for monitoring residual HIV burden in effectively treated individuals (2013) (46)
Alkylglycerol Prodrugs of Phosphonoformate Are Potent In Vitro Inhibitors of Nucleoside-Resistant Human Immunodeficiency Virus Type 1 and Select for Resistance Mutations That Suppress Zidovudine Resistance (2001) (46)
Cell surface CD4 downregulation and resistance to superinfection induced by a defective provirus of HIV-1. (1994) (45)
Incidence and prevalence of intrasubtype HIV-1 dual infection in at-risk men in the United States. (2013) (45)
Cell-mediated immune responses in humans after induced infection with influenza A virus. (1977) (45)
Studies on the mechanism of phospholipid storage induced by amantadine and chloroquine in Madin Darby canine kidney cells. (1982) (45)
Herpes viruses and HIV-1 drug resistance mutations influence the virologic and immunologic milieu of the male genital tract (2013) (45)
HIV-1 infection and expression in human colonic cells: infection and expression in CD4+ and CD4- cell lines. (1991) (45)
Long-term Safety and Efficacy of Zidovudine in Patients With Advanced Human Immunodeficiency Virus Disease (1991) (44)
Methamphetamine Use in HIV-infected Individuals Affects T-cell Function and Viral Outcome during Suppressive Antiretroviral Therapy (2015) (43)
Molecular and Cellular Analysis of Human Immunodeficiency Virus-Induced Apoptosis in Lymphoblastoid T-Cell-Line-Expressing Wild-Type and Mutated CD4 Receptors (1998) (42)
The intracellular distribution and antiviral activity of amantadine. (1981) (41)
Role of seminal shedding of herpesviruses in HIV Type 1 Transmission. (2013) (41)
Temperature-sensitive mutants of influenza A virus. XII. Safety, antigenicity, transmissibility, and efficacy of influenza A/Udorn/72-ts-1[E] recombinant viruses in human adults. (1976) (41)
Improved assays to measure and characterize the inducible HIV reservoir (2018) (41)
Immobilization of viral antigens on filter paper for a [125I]staphylococcal protein A immunoassay: a rapid and sensitive technique for detection of herpes simplex virus antigens and antiviral antibodies. (1979) (41)
Amino acid substitutions in HIV-1 reverse transcriptase with corresponding residues from HIV-2. Effect on kinetic constants and inhibition by non-nucleoside analogs. (1993) (40)
The use of pooled viral load testing to identify antiretroviral treatment failure (2009) (40)
Resistance, drug failure, and disease progression. (1994) (40)
The Effect of Zidovudine Treatment on Serum Neopterin and β2‐Microglobulin Levels in Mildly Symptomatic, HIV Type 1 Seropositive Individuals (1992) (40)
Comparison of methods to detect HIV dual infection. (2010) (39)
The prostate as a reservoir for HIV-1 (2004) (39)
Optimizing peptide matrices for identifying T‐cell antigens (2008) (38)
Microtiter format gene quantification by covalent capture of competitive PCR products: application to HIV-1 detection. (1993) (38)
Temperature sensitive mutants of influenza virus. IX. Genetic and biological characterization of TS-1[E] lesions when transferred to a 1972 (H3N2) influenza A virus. (1975) (38)
The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection. (2010) (38)
HIV-1 Clade B pol Evolution following Primary Infection (2013) (38)
Detecting human immunodeficiency virus RNA in peripheral blood mononuclear cells by nucleic acid hybridization. (1987) (38)
Ordered appearance of human immunodeficiency virus type 1 nucleic acids following high multiplicity infection of macrophages. (1992) (38)
Comparison of Sequencing by Hybridization and Cycle Sequencing for Genotyping of Human Immunodeficiency Virus Type 1 Reverse Transcriptase (2000) (38)
HIV evolution and escape. (2004) (36)
Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151. (1997) (36)
Antiretroviral Activity of Emtricitabine, a Potent Nucleoside Reverse Transcriptase Inhibitor (2000) (36)
Higher selection pressure from antiretroviral drugs in vivo results in increased evolutionary distance in HIV-1 pol. (1999) (36)
Productive in vitro infection of human umbilical vein endothelial cells and three colon carcinoma cell lines with HIV‐1 (1995) (36)
Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. The Zidovudine Epidemiology Group. (1992) (35)
Fluconazole treatment of persistent Cryptococcus neoformans prostatic infection in AIDS. (1991) (35)
Failure of attenuated temperature-sensitive influenza A (H3N2) virus to induce heterologous interference in humans to parainfluenza type 1 virus (1975) (35)
Treatment of Recurrent Genital Herpes Simplex Infections with Oral Acyclovir. A Controlled Trial (1984) (35)
Analysis of the SH3-binding region of HIV-1 nef: partial functional defects introduced by mutations in the polyproline helix and the hydrophobic pocket. (1999) (35)
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. (1990) (34)
Pleocytosis is associated with disruption of HIV compartmentalization between blood and cerebral spinal fluid viral populations. (2009) (34)
During Stably Suppressive Antiretroviral Therapy Integrated HIV-1 DNA Load in Peripheral Blood is Associated with the Frequency of CD8 Cells Expressing HLA-DR/DP/DQ (2015) (34)
Principles of HIV Resistance Testing and Overview of Assay Performance Characteristics (2000) (34)
Use of temperature-sensitive mutants of influenza A virus as live virus vaccine strains. Evaluation in laboratory animals, adults and children (1976) (34)
Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. ACTG Sequencing Working Group. AIDS Clinical Trials Group. (1998) (34)
Temperature-sensitive Mutants of Influenza A Virus: Response of Children to the Influenza A/Hong Kong/68-ts-1[E] (H3N2) and Influenza A/Udorn/72-ts-1[E] (H3N2) Candidate Vaccine Viruses and Significance of Immunity to Neuraminidase Antigen (1976) (34)
Persistent HIV-1-specific cellular responses despite prolonged therapeutic viral suppression (2002) (33)
Baseline Predictors of CD4 T‐Lymphocyte Recovery With Combination Antiretroviral Therapy (2002) (33)
Pooled Nucleic Acid Testing to Detect Antiretroviral Treatment Failure in Mexico (2011) (33)
Tat-independent replication of human immunodeficiency viruses. (1995) (33)
Temporal variation in HIV-specific IgG subclass antibodies during acute infection differentiates spontaneous controllers from chronic progressors (2017) (33)
HIV migration between blood and cerebrospinal fluid or semen over time. (2014) (33)
Virologic correlates of anti-CMV IgG levels in HIV-1-infected men. (2014) (33)
Concurrent human immunodeficiency virus and mycobacterial infection of macrophages in vitro does not reveal any reciprocal effect. (1992) (32)
Lipid prodrugs of phosphonoacids: greatly enhanced antiviral activity of 1-O-octadecyl-sn-glycero-3-phosphonoformate in HIV-1, HSV-1 and HCMV-infected cells, in vitro. (1996) (32)
Differential gene expression in HIV-infected individuals following ART. (2013) (31)
Ganciclovir prophylaxis for cochlear pathophysiology during experimental guinea pig cytomegalovirus labyrinthitis (1988) (31)
Viral Evolution in Response to the Broad-Based Retroviral Protease Inhibitor TL-3 (2001) (31)
A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. (1995) (31)
Long-term safety and efficacy of zidovudine in patients with advanced human immunodeficiency virus disease. Zidovudine Epidemiology Study Group. (1991) (31)
SMM-chemokines: a class of unnatural synthetic molecules as chemical probes of chemokine receptor biology and leads for therapeutic development. (2006) (30)
Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group. (1995) (30)
HIV downregulates interferon-stimulated genes in primary macrophages. (2013) (30)
Antiretroviral drug resistance: mechanisms, pathogenesis, clinical significance. (1996) (30)
Dideoxynucleosides are less inhibitory in vitro against human immunodeficiency virus type 2 (HIV-2) than against HIV-1 (1987) (30)
Risk factors for Kaposi's sarcoma in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group. (1994) (29)
A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team. (1999) (29)
Rapid typing of herpes simplex virus isolates by deoxyribonucleic acid:deoxyribonucleic acid hybridization (1980) (29)
Clinical, virologic, and immunologic correlates of HIV-1 intraclade B dual infection among men who have sex with men (2012) (29)
Methodologies for in vitro nucleic acid amplification and their applications. (1990) (29)
Fate of influenza A virion proteins after entry into subcellular fractions of LLC cells and the effect of amantadine. (1986) (29)
Greatly enhanced inhibition of human immunodeficiency virus type 1 replication in CEM and HT4-6C cells by 3'-deoxythymidine diphosphate dimyristoylglycerol, a lipid prodrug of 3'-deoxythymidine (1992) (28)
Anti-HIV Antibody Responses and the HIV Reservoir Size during Antiretroviral Therapy (2016) (28)
Clinical significance of drug resistance in human immunodeficiency virus. (1995) (28)
Quantification of Total and 2-LTR (Long terminal repeat) HIV DNA, HIV RNA and Herpesvirus DNA in PBMCs. (2015) (27)
A rapid enzyme lmmunofiltration technique using monoclonal antibodies to serotype herpes simplex virus (1982) (27)
Transcriptomic Analysis Implicates the p53 Signaling Pathway in the Establishment of HIV-1 Latency in Central Memory CD4 T Cells in an In Vitro Model (2016) (27)
Incidence and Natural History of Cytomegalovirus Disease in Patients With Advanced Human Immune Deficiency Virus Disease Treated With Zidovudine: The Zidovudine Epidemiology Study Group (1993) (27)
A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A (1997) (27)
Genetic Basis of Hypersusceptibility to Protease Inhibitors and Low Replicative Capacity of Human Immunodeficiency Virus Type 1 Strains in Primary Infection (2004) (27)
In vitro differentiation of monocytoid THP-1 cells affects their permissiveness for HIV strains: a model system for studying the cellular basis of HIV differential tropism. (1993) (26)
Azidothymidine in the treatment of AIDS. (1988) (26)
A synthetic bivalent ligand of CXCR4 inhibits HIV infection. (2013) (26)
Drug resistance in viruses. (1994) (26)
Mixed effects of suberoylanilide hydroxamic acid (SAHA) on the host transcriptome and proteome and their implications for HIV reactivation from latency. (2015) (26)
Virological suppression and clinical management in response to viremia in South African HIV treatment program: A multicenter cohort study (2020) (26)
Assessing intra-lab precision and inter-lab repeatability of outgrowth assays of HIV-1 latent reservoir size (2018) (26)
A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. (1990) (26)
Consensus symposium on combined antiviral therapy (1996) (25)
Broadly Increased Sensitivity to Cytotoxic T Lymphocytes Resulting from Nef Epitope Escape Mutations 1 (2003) (25)
Risk Factors for Kaposi's Sarcoma in Patients With Advanced Human Immunodeficiency Virus Disease Treated With Zidovudine (1994) (25)
Rapid Sequencing of Complete env Genes from Primary HIV-1 Samples. (2016) (25)
Summary of the international consensus symposium on management of HIV, CMV and hepatitis virus infections. (1998) (25)
Rapid serological technique for typing herpes simplex viruses (1982) (25)
Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance (2008) (25)
Maintenance of Nef-Mediated Modulation of Major Histocompatibility Complex Class I and CD4 after Sexual Transmission of Human Immunodeficiency Virus Type 1 (2007) (25)
Salvage therapy for zidovudine-intolerant HIV-infected patients with alternating and intermittent regimens of zidovudine and dideoxycytidine. (1990) (25)
Antiviral resistance in clinical practice. (1995) (25)
Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication (2000) (25)
Vitamin D3 compounds regulate human immunodeficiency virus type 1 replication in U937 monoblastoid cells and in monocyte‐derived macrophages (1993) (24)
AIDS Clinical Trials Group: phase I/II study of combination 2',3'-dideoxycytidine and zidovudine in patients with acquired immunodeficiency syndrome (AIDS) and advanced AIDS-related complex. (1990) (24)
Synthesis and antiviral activity of 3'-azido-3'-deoxythymidine triphosphate distearoylglycerol: a novel phospholipid conjugate of the anti-HIV agent AZT. (1994) (24)
Phosphatidylazidothymidine. Mechanism of antiretroviral action in CEM cells. (1991) (24)
The efficiency of single genome amplification and sequencing is improved by quantitation and use of a bioinformatics tool. (2009) (24)
The tolerance for zidovudine plus thrice weekly or daily trimethoprim-sulfamethoxazole with and without leucovorin for primary prophylaxis in advanced HIV disease. California Collaborative Treatment Group. (1995) (24)
Antiretroviral drug resistance. (1991) (24)
HIV Therapeutics (1996) (24)
Enzyme immunofiltration technique for rapid diagnosis of herpes simplex virus eye infections in a rabbit model (1982) (24)
COVID-19 vaccines: implementation, limitations and opportunities. (2021) (23)
Estimating selection pressures on HIV‐1 using phylogenetic likelihood models (2008) (23)
A computer-based, image-analysis method to quantify HIV-1 infection in a single-cycle infectious center assay. (2006) (23)
HIV-1 neutralizing antibody response and viral genetic diversity characterized with next generation sequencing. (2015) (23)
Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4+ T cells (2013) (23)
Herpes simplex virus type 2 infection does not influence viral dynamics during early HIV-1 infection. (2007) (23)
Benefits and limitations of testing for resistance to HIV drugs. (2004) (23)
Phosphatidyl-2',3'-dideoxy-3'-thiacytidine: synthesis and antiviral activity in hepatitis B-and HIV-1-infected cells. (1995) (23)
IDEPI: Rapid Prediction of HIV-1 Antibody Epitopes and Other Phenotypic Features from Sequence Data Using a Flexible Machine Learning Platform (2014) (23)
The challenge of immune control of immunodeficiency virus. (1999) (22)
Antibody responses in primary HIV-1 infection (2008) (22)
Introduction: challenges to finding a cure for HIV infection (2011) (22)
Using HIV Sequence and Epidemiologic Data to Assess the Effect of Self-referral Testing for Acute HIV Infection on Incident Diagnoses in San Diego, California. (2016) (21)
Relative efficacy of T cell stimuli as inducers of productive HIV-1 replication in latently infected CD4 lymphocytes from patients on suppressive cART. (2017) (21)
Impact of seminal cytomegalovirus replication on HIV‐1 dynamics between blood and semen (2012) (21)
Different Plasma Markers of Inflammation Are Influenced by Immune Recovery and cART Composition or Intensification in Treated HIV Infected Individuals (2014) (21)
Transcriptional Modulation of Human Endogenous Retroviruses in Primary CD4+ T Cells Following Vorinostat Treatment (2018) (21)
Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. (2010) (21)
Human Immunodeficiency Virus-Associated Neurobehavioural Disorder (1988) (21)
Biochemical genetic analysis of 2',3'-dideoxyadenosine metabolism in human T lymphocytes. (1988) (21)
Mapping Protease Inhibitor Resistance to Human Immunodeficiency Virus Type 1 Sequence Polymorphisms within Patients (2007) (21)
Phosphatidylazidothymidine and phosphatidyl-ddC: assessment of uptake in mouse lymphoid tissues and antiviral activities in human immunodeficiency virus-infected cells and in Rauscher leukemia virus-infected mice (1994) (20)
Dynamics of Viral Evolution and Neutralizing Antibody Response after HIV-1 Superinfection (2013) (20)
Alkoxy propane prodrugs of foscarnet: effect of alkyl chain length on in vitro antiviral activity in cells infected with HIV-1, HSV-1 and HCMV. (1997) (20)
Temperature-sensitive mutants of influenza A virus. XIV. Production and evaluation of influenza A/Georgia/74-ts-1[E] recombinant viruses in human adults. (1977) (20)
Detection of HIV-1 in alternative specimen types using the APTIMA HIV-1 RNA Qualitative Assay. (2009) (20)
Synthesis and in vitro activity of long-chain 5'-O-[(alkoxycarbonyl)phosphinyl]-3'-azido-3'-deoxythymidines against wild-type and AZT- and foscarnet-resistant strains of HIV-1. (1997) (20)
Histone deacetylase inhibitors induce complex host responses that contribute to differential potencies of these compounds in HIV reactivation (2019) (19)
Enzyme immunofiltration staining assay for immediate diagnosis of herpes simplex virus and varicella-zoster virus directly from clinical specimens (1987) (19)
HIV drug resistance. (1994) (19)
Antiviral therapy of HIV infection. (1991) (19)
Clinical Virology, 3rd Edition (2010) (19)
Lack of Association between Acyclovir Use and Survival in Patients with Advanced Human Immunodeficiency Virus Disease Treated with Zidovudine (1995) (19)
No evidence of posttreatment control after early initiation of antiretroviral therapy (2015) (18)
Demonstration of a non-temperature-sensitive growth-restricting mutation in a ts mutant of influenza A virus: implications for live virus vaccine development. (1977) (18)
Safety and antiviral activity of combination therapy with zidovudine, zalcitabine, and two doses of interferon-alpha2a in patients with HIV. AIDS Clinical Trials Group Study 197. (1997) (18)
A case report of disseminated histoplasmosis and concurrent cryptococcal meningitis in a patient treated with ruxolitinib (2019) (18)
Gene expression before HAART initiation predicts HIV-infected individuals at risk of poor CD4+ T-cell recovery (2010) (18)
Editorial overview: Antivirals and resistance: Advances and challenges ahead (2014) (18)
Rapid screening of phenotypic resistance to nevirapine by direct analysis of HIV type 1 reverse transcriptase activity in plasma. (1999) (18)
Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study). (2005) (17)
Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients (2010) (17)
Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc (2017) (17)
Quantitation of Integrated HIV Provirus by Pulsed-Field Gel Electrophoresis and Droplet Digital PCR (2018) (17)
:Clinical Virology, 2nd Edition (2002) (17)
Aberrant and unstable expression of immunoglobulin genes in persons infected with human immunodeficiency virus. (1998) (17)
Normal physiology and HIV pathophysiology of human T-cell dynamics. (2000) (17)
Stimulation of HIV replication in mononuclear phagocytes by leukemia inhibitory factor. (1994) (16)
Combination therapy with recombinant human soluble CD4-immunoglobulin G and zidovudine in patients with HIV infection: a phase I study. (1995) (16)
A rapid radioimmunoassay using 125I-labeled staphylococcal protein A for antibody to varicella-zoster virus. (1981) (16)
Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat (2012) (16)
Protease polymorphisms in HIV-1 subtype CRF01_AE represent selection by antiretroviral therapy and host immune pressure (2010) (15)
Sequence clusters in human immunodeficiency virus type 1 reverse transcriptase are associated with subsequent virological response to antiretroviral therapy. (1999) (15)
Transplantation of CCR5∆32 Homozygous Umbilical Cord Blood in a Child With Acute Lymphoblastic Leukemia and Perinatally Acquired HIV Infection (2018) (15)
Temperature-Sensitive mutants of influenza virus. VII. Transfer of the TS-1[E] lesions to a wild-type influenza A virus with the HON1 surface antigens. (1975) (15)
Evaluation of the Aptima HIV-1 Quant Dx Assay for HIV-1 RNA Quantitation in Different Biological Specimen Types (2017) (15)
The AIDS Clinical Trials Group (1990) (15)
Discovery and characterization of an HIV-1 Tat antagonist. (1992) (14)
Inhibition of HIV-1 by Octadecyloxyethyl Esters of (S)-[3-Hydroxy-2-(Phosphonomethoxy)Propyl] Nucleosides and Evaluation of Their Mechanism of Action (2011) (14)
Peripheral Nerve Function in Persons with Asymptomatic or Minimally Symptomatic HIV Disease: Absence of Zidovudine Neurotoxicity (1991) (14)
The Use of High Performance Liquid Chromatography to Speciate and Characterize the Epidemiology of Mycobacteria. (2011) (14)
Surface CD4 expression modulated by a cellular factor induced by HIV type 1 infection. (2003) (14)
Nailing down another HIV target (1998) (14)
Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor (1994) (14)
Characterization of a macrophage-tropic HIV strain that does not alter macrophage cytokine production yet protects macrophages from superinfection by vesicular stomatitis virus. (1990) (14)
Summary of the III International Consensus Symposium on Combined Antiviral Therapy. (1998) (13)
The use of staphylococcal protein A in diagnostic virology. (1983) (13)
Clinical Virology, Third Edition (2009) (13)
Pill Burden Influences the Association Between Time‐Based Prospective Memory and Antiretroviral Therapy Adherence in Younger But Not Older HIV‐Infected Adults (2016) (13)
Immunologic resilience and COVID-19 survival advantage (2021) (13)
Herpes Simplex Virus Type 2 Acquisition During Recent HIV Infection Does Not Influence Plasma HIV Levels (2008) (13)
HIV-1 Preintegration Complexes Preferentially Integrate into Longer Target DNA Molecules in Solution as Detected by a Sensitive, Polymerase Chain Reaction-based Integration Assay* (2001) (13)
Cell-intrinsic mechanism involving Siglec-5 associated with divergent outcomes of HIV-1 infection in human and chimpanzee CD4 T cells (2012) (13)
A Combined Screening Platform for HIV Treatment Failure and Resistance (2012) (13)
A rapid enzyme immunofiltration technique using monoclonal antibodies to serotype herpes simplex virus. (1982) (13)
Myroides injenensis Bacteremia and Severe Cellulitis. (2019) (13)
Predictors of virologic response in persons who start antiretroviral therapy during recent HIV infection (2014) (13)
Drug resistance in relation to pathogenesis. (1995) (12)
Improved Survival and Reduced Clinical Progression in HIV-Infected Patients with Advanced Disease Treated with Saquinavir plus Zalcitabine (1998) (12)
Mission now possible for AIDS fund (2001) (12)
Phospholipid prodrug inhibitors of the HIV protease. Antiviral activity and pharmacokinetics in rats. (1994) (12)
Biological importance and cooperativity of HIV-1 regulatory gene splice acceptors. (1994) (12)
Human immunodeficiency virus. (2009) (11)
Editorial Commentary: Extending HIV drug resistance testing to low levels of plasma viremia. (2014) (11)
How drug resistance arises. (1998) (11)
Codon volatility does not reflect selective pressure on the HIV-1 genome. (2005) (11)
Encyclopedia of AIDS (2018) (11)
Select resistance-associated mutations in blood are associated with lower CSF viral loads and better neuropsychological performance. (2009) (11)
Higher HIV-1 genetic diversity is associated with AIDS and neuropsychological impairment. (2012) (11)
Characterizing the multiplicity of HIV founder variants during sexual transmission among MSM (2016) (11)
Intrasubtype B HIV-1 Superinfection Correlates with Delayed Neutralizing Antibody Response (2017) (11)
Synthesis and hypnotic and anti-human immunodeficiency virus-1 activities of N3-substituted 2'-deoxy-2'-fluorouridines. (1994) (11)
Associations between phylogenetic clustering and HLA profile among HIV-infected individuals in San Diego, California. (2012) (11)
Playing chess with reverse transcriptase (1993) (11)
Controlled trial of oral acyclovir in the therapy of recurrent herpes simplex genitalis. A preliminary report. (1982) (11)
AZT resistance in isolates of HIV. (1991) (11)
Intact Human Immunodeficiency Virus (HIV) Reservoir Estimated by the Intact Proviral DNA Assay Correlates With Levels of Total and Integrated DNA in the Blood During Suppressive Antiretroviral Therapy. (2021) (11)
Recurrent Pneumocystis carinii pneumonia in a child with hypogammaglobulinemia. (1973) (11)
Sexual transmission of predicted CXCR4-tropic HIV-1 likely originating from the source partner's seminal cells. (2012) (10)
Specificity of the local secretory antibody to influenza A virus infection. (1974) (10)
Attenuated influenza virus in normal adults: role of pulmonary function studies in vaccine trials. (1976) (10)
Decreased HIV type 1 transcription in CCR5-Δ32 heterozygotes during suppressive antiretroviral therapy. (2014) (10)
Broad Advances in Understanding HIV Resistance to Antiretrovirals: Report on the XVII International HIV Drug Resistance Workshop (2008) (10)
Prevalence of Psychiatric Disorders Among Men Infected With Human Immunodeficiency Virus (2015) (10)
Erratum: Higher selection pressure from antiretroviral drugs in vivo results in increased evolutionary distance in HIV-1 pol (Virology (1999) 259:1 (154-165)) (1999) (10)
Comparative analysis of HIV type 1 genotypic resistance across antiretroviral trial treatment regimens. (2000) (10)
Analytical antiretroviral therapy interruption does not irreversibly change preinterruption levels of cellular HIV. (2018) (10)
In Vitro Evaluation of Experimental Agents for Anti‐HIV Activity (1993) (10)
Antiviral Drug Discovery To Address the COVID-19 Pandemic (2020) (10)
Human Immunodeficiency Virus Replication in AIDS Patients with Mycobacterium avium Complex Bacteremia: A Case Control Study (1998) (10)
Public access to experimental drug therapy: AIDS raises yet another conflict between freedom of the individual and welfare of the individual and public. (1989) (10)
Factors Associated With Persistence of Plasma HIV-1 RNA During Long-term Continuously Suppressive Firstline Antiretroviral Therapy (2018) (9)
Poor agreement between 2 assays for measuring low levels of HIV-1 viral load. (2009) (9)
Natural history of advanced HIV disease in patients treated with zidovudane (1992) (9)
Aberrant and Unstable Expression of Immunoglobulin Genes in Persons Infected With Human Immunodeficiency Virus (1998) (9)
In vitro Anti-HIV-1 Activity of sn-2-Substituted 1-O-Octadecyl-sn-Glycero-3-Phosphonoformate Analogues and Synergy with Zidovudine (2000) (9)
Clinical Implications of Resistance to Antiretrovirals: New Resistance Technologies and Interpretations (2008) (9)
The impact of zidovudine compared with didanosine on health status and functioning in persons with advanced HIV infection and a varying duration of prior zidovudine therapy. AIDS Clinical Trials Group 116/117 Study Group. (1996) (9)
Response to Comment on "The Origins of Sexually Transmitted HIV Among Men Who Have Sex with Men" (2010) (9)
HIV-associated neurocognitive disorder is associated with HIV-1 dual infection (2016) (9)
The clinical significance of drug-resistance mutants of human immunodeficiency virus. (1992) (9)
The treatment of HIV infection. Azidothymidine (AZT) and other new antiviral drugs. (1988) (9)
Resistance, Drug Failure, and Disease Progression (1994) (8)
1 A New Perspective on V 3 Phenotype Prediction (2002) (8)
Safety and Efficacy of zidovudine in asymptomatic HIV infected individuals withless than 500 CD4+ cells/mm3. (1990) (8)
Using ultradeep pyrosequencing to study HIV-1 coreceptor usage in primary and dual infection. (2013) (8)
Predictive Value of Pharmacokinetics-Adjusted Phenotypic Susceptibility on Response to Ritonavir-Enhanced Protease Inhibitors (PIs) in Human Immunodeficiency Virus-Infected Subjects Failing Prior PI Therapy (2009) (8)
Barriers to a Cure: New concepts in targeting and eradicating HIV-1 reservoirs (2013) (8)
Selection of zidovudine-resistant variants of human immunodeficiency virus by therapy. (1992) (8)
Evaluation of a Highly Sensitive Qualitative Human Immunodeficiency Virus Type 1 (HIV-1) RNA Assay for Detection of HIV-1 Suppression (2009) (8)
Antiproliferative effects of enediynes on AIDS-derived Kaposi's sarcoma cells. (1994) (8)
Impairment in T-lymphocyte responses during early infection with the human immunodeficiency virus (1989) (7)
Intact HIV reservoir estimated by the intact proviral DNA assay correlates with levels of total and integrated DNA in the blood during suppressive antiretroviral therapy. (2020) (7)
The treatment of HIV infection. (1988) (7)
Assessing suitability of next-generation viral outgrowth assays as proxies for classic QVOA to measure HIV-1 latent reservoir size. (2020) (7)
Correlation Between CD4+ Counts and Prevalence of Cytomegalovirus Retinitis and Human Immunodeficiency Virus-Related Noninfectious Retinal Vasculopathy in Patients with Acquired Immune Deficiency Syndrome (1993) (7)
Replicate Aptima Assay for Quantifying Residual Plasma Viremia in Individuals on Antiretroviral Therapy (2020) (7)
A phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with >300 CD4 cells who were antiretroviral naive (ACTG 298). (2002) (7)
Synthesis and anti-HIV activity of 6-substituted purine 2'-deoxy-2'-fluororibosides (1994) (7)
Use of temperature-sensitive mutants for live, attenuated influenza-virus vaccines. (1979) (7)
Anabolism and Mechanism of Action of Ro24‐5098, an Isomer of 2′,3′‐Dideoxyadenosine (ddA) with Anti‐HIV Activity (1990) (7)
Designing phase II studies of chemotherapy for HIV infection using CD4 as an end-point. (1993) (7)
Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV. (2018) (6)
Assessing the Suitability of Next-Generation Viral Outgrowth Assays to Measure Human Immunodeficiency Virus 1 Latent Reservoir Size (2020) (6)
Protease uninhibited (1995) (6)
Replication competence of virions induced from CD4+ lymphocytes latently infected with HIV (2019) (6)
The Future of HIV-1 Therapeutics. Resistance Is Futile? (2015) (6)
The impact of concomitant viral pathogens on the course of Pneumocystis carinii pneumonia. (1991) (6)
Random important alterations in HIV-1 viral quasispecies after antiviral treatment. (1996) (6)
New strategies to combat HIV drug resistance. (1996) (6)
Synthesis of the Fluoromethyl Derivatives of Carbocyclic Oxetanocin A (1996) (6)
Oxygen tensions and mycobacterial infections. (1992) (6)
The Future of HIV-1 Therapeutics (2015) (6)
Viral drug resistance (1990) (6)
Interlaboratory Measurement Differences in Intracellular Carbovir Triphosphate Concentrations in HIV‐Infected Patients: Sources of Variability in Processing, Shipping, and Quantitation (2010) (6)
Arizona hinshawii Infection of an Atherosclerotic Abdominal Aorta (1981) (5)
Immunoenzymatic staining of viral and chlamydial antigens in cell culture. (1985) (5)
Equal inhibition of HIV replication by stereoisomers of phosphatidyl-azidothymidine. Lack of stereospecificity of lysosomal phospholipase A1. (1992) (5)
Success hinges on support for treatment (2001) (5)
A Plea for Justice for Jailed Medical Workers (2006) (5)
Increased HIV-1 superinfection risk in carriers of specific human leukocyte antigen alleles (2017) (5)
A randomized controlled clinical trial on the impact of CCR5 blockade with maraviroc in early infection on T-cell dynamics (2016) (5)
Viral and antiretroviral dynamics in HIV mother-to-child transmission fluids (VADICT) – Protocol and data analysis plan for a cohort study (2019) (5)
8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada (2015) (5)
HIV and Hepatitis Virus Resistance to Antivirals: Review of Data from the Xix International HIV and Hepatitis Virus Drug Resistance Workshop and Curative Strategies (2011) (5)
Antiviral Therapy (2016) (5)
Recovery of infectious HIV following the passage of apoptotic cellular debris through phagocytic macrophages. (1993) (5)
Elements of the Human Immune System: Studies of Mature Lymphoid Cells Following Xenotransplantation to Scid Mice (1989) (5)
Arizona hinshawii infection of an atherosclerotic abdominal aorta. (1981) (5)
Summary of the II international consensus symposium on combined antiviral therapy and implications for future therapies (1997) (5)
A novel codon insert in protease of clade B HIV type 1. (2009) (5)
Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team. (1996) (4)
Upregulation of BST-2/Tetherin by HIV Infection In Vivo (2012) (4)
HIV infectivity is not augmented by treatment with trypsin, Factor Xa or human mast-cell tryptase. (1992) (4)
Nucleic Acid Probes to Detect Viral Diseases (1986) (4)
Erratum: Dynamics of T cell responses in HIV infection (The Journal of Immunology (2002) 168 (3660-3666)) (2002) (4)
Antibody Response to Achromobacter xylosoxidans during HIV Infection Is Associated with Lower CD4 Levels and Increased Lymphocyte Activation (2013) (4)
Medical Outcomes Study HIV Health Survey (2020) (4)
HIV: Finding latent needles in a haystack (2017) (4)
Effect of interferon on the replication of Sendai virus. (1970) (4)
Key Reports from the XV International HIV Drug Resistance Workshop 2006 (2007) (3)
Lack of association between acyclovir use and survival in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group. (1995) (3)
Pasteurella infections of the head and neck. (1986) (3)
The role of viral dynamics in the pathogenesis of HIV disease and implications for antiviral therapy (2004) (3)
HIV viral load monitoring. (1999) (3)
Tree models for the evolution of drug resistance (2003) (3)
Determination of influenzavirus neuraminidase inhibition titres. (1975) (3)
Heterogeneity and Public Health in the Global HIV / AIDS Epidemic (2001) (3)
Human immunodeficiency virus. Protease uninhibited. (1995) (3)
Cell-associated viral RNA expression during acute infection with HIV type 1. (1998) (3)
The Limitations of Simplicity (1998) (3)
Playing with evolution requires planning. (1996) (3)
Human immunodeficiency virus. Playing chess with reverse transcriptase. (1993) (3)
Expression of human immunodeficiency virus-1 in human colonic cells (1991) (3)
Editorial Commentary: HIV Is Putting Up Less Resistance. (2016) (3)
Second European Round Table on the Future Management of HIV (2015) (3)
Novel Non‐Nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 (HIV‐1) Reverse Transcriptase. Part 4. 2‐Substituted Dipyridodiazepinones as Potent Inhibitors of Both Wild‐Type and Cysteine‐181 HIV‐1 Reverse Transcriptase Enzymes. (1996) (3)
Progress in Basic and Clinical Research on HIV Resistance: Report on the XVIII International HIV Drug Resistance Workshop (2009) (3)
2022 update of the drug resistance mutations in HIV-1. (2022) (3)
An individual-based epidemiological model for the transmission of drug resistant HIV (2002) (2)
Emergence of mutant HIV reverse transcriptase conferring resistance to AZT. (1992) (2)
Standardized peripheral blood mononuclear cell culture assay for zidovudine susceptibility testing of clinical human immunodeficiency virus type 1 isolates: effect of reducing the numbers of replicates and concentrations (1997) (2)
The role of surface CD4 in HIV-induced apoptosis. (1995) (2)
HIV: Cure by killing (2015) (2)
Human immunodeficiency virus replication in AIDS patients with Mycobacterium avium complex bacteremia: a case control study. California Collaborative Treatment Group. (1998) (2)
Development of the HIV360 international core set of outcome measures for adults living with HIV: A consensus process (2021) (2)
Interferon interactions with HIV1 in macrophages. (1994) (2)
Can HIV infection be cured? (1996) (2)
Synthesis and Anti‐HIV Activity of a Novel Series of Isomeric Dideoxynucleosides (1990) (2)
Molecular Features of the V1–V4 Coding Region of Sexually Transmitted Human Immunodeficiency Virus Type 1 (2017) (2)
Retroviruses et opportunistic infections '99. (1999) (2)
Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines Panel. (2003) (2)
The first blow is half the battle. (1997) (2)
Colorectal Disorders in Acute Human Immunodeficiency Virus Infection: A Case Series (2016) (2)
Synthesis and Anti-HIV Activity of 2-Substituted 2′-Deoxy-2′-fluoroadenosines (1994) (2)
Developments in rapid viral diagnosis. (1987) (2)
Basic and Translational Research of Chemokine Ligands and Receptors and Development of Novel Therapeutics (2006) (2)
Early versus delayed treatment of HIV infection. Zidovudine should be given before symptoms develop. (1995) (1)
Disregarding drug resistance mutations without peril. (2021) (1)
Shining the RNA-Seq microscope on models of HIV latency (2015) (1)
Using mixtures of amino acids to detect individual- and population-level selection of HIV-1 protease (2005) (1)
Is France Once Again Looking for a Scapegoat? (2021) (1)
Nevirapine, didanosine, and zidovudine for patients with HIV: the INCAS trial. Italy, Netherlands, Canada, and Australia. (1999) (1)
UpdateoftheDrugResistanceMutationsinHIV-1: Spring 2008 (2008) (1)
Magnitude and specificity of temporal gene expression during HIV-1 infection of a CD4+ T cell (1999) (1)
Synthesis and Hypnotic and Anti-Human Immunodeficiency Virus-1 Activities of N3-Substituted 2′-Deoxy-2′-fluorouridines. (1994) (1)
Research initiatives in studies of antiviral resistance and consensus points and recommendations. (1995) (1)
Relationship of KSHV/HHV-8 Replication to Extent and Course of Kaposi's Sarcoma and Response to Therapy. (1998) (1)
Antiretroviral therapy and clinical trials: what now? (1996) (1)
Novel codon insert in HIV type 1 clade B reverse transcriptase associated with low-level viremia during antiretroviral therapy. (2014) (1)
Recommendations of the International AIDS Antiretroviral Treatment of Adult HIV Infection : 2008 (2008) (1)
Integrated proteomics and transcriptomics analyses identify novel cell surface markers of HIV latency. (2022) (1)
Synthesis and in vitro antiviral activity of long-chain 5′-O-alkoxycarbonylphosphinyl)-3′-azido-3′-deoxythymidines against drug-sensitive and AZT- or PFA-resistant human immunodeficiency virus type-1 (HIV-1) (1997) (1)
Relationship of HHV-8 Peripheral Blood Mononuclear Cell Burden to Immunodeficiency, Opportunistic Infections, Response to Therapy, and Stage of Kaposi's Sarcoma: 80 (1997) (1)
Inconsistent reversal of HIV-1 latency ex vivo by antigens of HIV-1, CMV, and other infectious agents (2020) (1)
A case cluster demonstrating the relationship between HLA concordance and virologic and disease outcomes in human immunodeficiency virus infection. (2014) (1)
The Xivth International HIV Drug Resistance Workshop, Quebec City, Canada, June 2005 (2005) (1)
Reply to Ambrosioni et al. (2018) (0)
Dissecting the Neutralizing Antibody Speciﬁcities of Broadly Neutralizing Sera from Human Immunodeﬁciency Virus Type 1-Infected Donors (cid:1) (2007) (0)
Cell-intrinsic mechanism involving Siglec-5 associated with divergent outcomes of HIV-1 infection in human and chimpanzee CD4 T cells (2012) (0)
Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat (2012) (0)
Antiviral Therapy in 2003 (2001) (0)
syndrome.with acquired immunodeficiency complex strains isolated from the blood of macrophages of Mycobacterium avium Characterization and growth in human (2014) (0)
Chapter 34 – HIV Drug Susceptibility Testing (2004) (0)
CTL responses to HIV-1 during acute and chronic infection (2008) (0)
CHAPTER 35 Nucleic Acid Probes to Detect Viral Diseases (0)
Development of a simple clinical method to screen for AIDS virus in blood donors in underdeveloped countries. (1987) (0)
Mark Wainberg. (2017) (0)
Drug Resistance Mutations in HIV-1. (2002) (0)
SKEWED AND UNSTABLE B-CELL REPERTOIRE IN SERIAL BLOOD SAMPLES OF HIV INFECTED PATIENTS. POTENTIAL ROLE IN THE INDUCTION OF AIDS-ASSOCIATED LYMPHOMA: 138 (1997) (0)
Consensus symposium on combined antiviral therapy. International Society for Antiviral Research and the National Institutes of Allergy and Infectious Diseases. (1996) (0)
Antiretroviral drug resistance in resource-limited settings (2012) (0)
Escape Mutations Lymphocytes Resulting from Nef Epitope Broadly Increased Sensitivity to Cytotoxic T (2013) (0)
A Phase II Randomized Study of HIV-Specific T-Cell GeneTherapy in Subjects with Undetectable Plasma Viremiaon Combination Antiretroviral Therapy (2002) (0)
Epstein-Varr virus. (2009) (0)
Simultaneous detection of antibody to the human immunodeficiency virus and of the surface antigen of hepatitis B virus in human serum. (1988) (0)
HIV disease: Pathogenesis and therapy (1991) (0)
Synthesis and Anti-HIV Activity of 2-Substituted 2′-Deoxy-2′- fluoroadenosines. (1995) (0)
AreLessInhibitory InVitro against Human Immunodeficiency Virus Type2(HIV-2) thanagainst HIV-1 (1987) (0)
The Depth of CTL Epitope Coverage Correlates with Strength of Selection in Gag p17 for Subtype B but not Subtype C (2008) (0)
Contending with the challenges of HIV: a first-hand account (2012) (0)
Early Versus Delayed Treatment of HIV Infection (2012) (0)
P04-03. Cross-clade neutralization analysis of plasmas from clade B, C and CRF01_AE HIV-infected donors (2009) (0)
dividuals already infected with HIV should thus continue vigi- lant personal protection through safe-sex practices or clean needle use for injection drugs, even if their risk exposures are with other HIV-infected people. (2009) (0)
Antibody toaSynthetic Oligopeptide inSubjects atRiskfor HumanImmunodeficiency Virus Infection RICHARDS.SMITH,'* ROBERTB.NASO,1JONROSEN,' ALICEWHALLEY,' YAO-LINGHOM,'KENWAY (1987) (0)
Detection de la resistance a la 3'-azido-3'-desoxythymidine (1992) (0)
Analysing the genotypic basis of hypersusceptibility to amprenavir in HIV from antiretroviral-naive patients (2002) (0)
Zidovudine resistance of human immunodeficiency virus. Discussion (1990) (0)
Novel peptide prodrugs: Lipid derivatization of protease inhibitor enhances in vivo plasma half life (1994) (0)
IAS-USA Board of Directors (2011) (0)
Influence ofHostCell TypeandV3LoopoftheSurface Glycoprotein on Susceptibility ofHumanImmunodeficiency Virus Type1toPolyanion Compounds (1994) (0)
RECENT PROGRESS IN THE DEVELOPMENT AND ASSESSMENT OF LIVE ATTENUATED VACCINES Chairman: PROFESSOR F. M. DAVENPORT (2008) (0)
The Safety and Efficacy of Zidovudine (AZT) in the Treatment of Subjects with Mildly Symptomatic Human Immunodeficiency Virus Type 1 (HIV) Infection (2020) (0)
Book Review: Clinical Virology (1998) (0)
Human immunodeficiency virus type 1 clade B superinfection (2018) (0)
Optimal Infectivity InVitroofHumanImmunodeficiency Virus Type1Requires an Intact nefGene (1994) (0)
Distinct HIV reservoir measures correlate with defective but not intact pro-viral DNA (2019) (0)
Decreased Thymic Output in HIV Infection Evidence for Increased T Cell Turnover and (2001) (0)
Board – – – – — — – — — — — — — — IAS – USA Board of Directors — — — — – — — — — — (2018) (0)
Inconsistent reversal of HIV-1 latency ex vivo by antigens of HIV-1, CMV, and other infectious agents (2020) (0)
A Conversation Among the IAS-USA Board of Directors: Hot Topics and Emerging Data in HIV Research and Care. (2017) (0)
Emergence of Human Immunodeficiency Virus Drug Resistance (2000) (0)
antivirals and resistance: advances and challenges ahead. (2014) (0)
Procedes conçu pour augmenter une reaction de lymphocytes t cytotoxiques in vivo (2001) (0)
Transmission and fitness of drug resistant strains of HIV (2000) (0)
Dynamics of Viral Evolution and Neutralizing Antibody (2013) (0)
The clinical use of anti-HIV agents (1990) (0)
Workshop: Error correction, noise filtering, and phylogenetic analysis of HIV sequences using the 454 platform (2012) (0)
Sequence Note: A New Perspective on V3 Phenotype Prediction (2003) (0)
Fitness of Drug-Resistant Human Immunodeﬁciency Virus against a Background of Evolving Antiretroviral Therapy (2010) (0)
Advances in the Management of HIV-HBV Coinfection (2006) (0)
Are Broadly Neutralizing Antibodies against HIV-1 Unusual? (47.32) (2007) (0)
19 2-HALO-2′,3′-DIDEOXYADENOSINES: METABOLICALLY STABLE DIDEOXYNUCLEOSIDES WITH ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS (HIV) (1988) (0)
Limitations of Current Therapies for HIV-1 Infection (2019) (0)
The Importance of nes in the Induction of Human Immunodeficiency Virus Type 1 Replication from Primary Quiescent CD 4 Lymphocytes (2003) (0)
Replication competence of virions induced from CD4+ lymphocytes latently infected with HIV (2019) (0)
Compositions and methods to evaluate the use of viral receptor / correceptor and virus entry inhibitors using recombinant virus assays (2003) (0)
2-halo-2',3'-dideoxyadenosines: metabolically stable dideoxynucleosides with activity against the human immunodeficiency virus (HIV). (1989) (0)
A microarray-based HPV typing analysis for anal dysplasia (2009) (0)
Prolonged Zidovudine Therapy: Confounded by Pneumocystis carinii Prophylaxis?-Reply (1990) (0)
Scarlet fever and group A wound infection traced to streptococcal surgical (1977) (0)
Likely Possible Unlikely Technical Cut-off Clinical Cut-off Resistance Index Efficient Drug Non Efficient Drug (2003) (0)
Large in vivo expansion and subsequent partial contraction of a T cell clone carrying a defective HIV genome reflect the dynamics of the HIV reservoir during ART (2019) (0)
semen is associated with higher levels of proviral HIV DNA and CD 4 + T cell activation during antiretroviral treatment (2014) (0)
Arthropod-borne falviviruses. (2009) (0)
Transmitted HIV drug resistance: effect of treatment intensification in limiting the epidemic (2005) (0)
Characterization andGrowthinHumanMacrophages of Mycobacterium aviumComplex Strains Isolated fromtheBlood ofPatients withAcquired Immunodeficiency Syndrome (1990) (0)
Effects of amino acid and synonymous polymorphisms in HIV-1 protease on viral fitness (2003) (0)
The creation of a microarray data analysis system and its application to htlv-i-induced transformation (2002) (0)
HIV Is Putting Up Less Resistance (2016) (0)
Edinburgh Research Explorer Adaptation to human populations is revealed by within-host polymorphisms in HIV-1 and hepatitis C virus (2018) (0)

This paper list is powered by the following services:

Other Resources About Douglas Richman

en.wikipedia.org

What Schools Are Affiliated With Douglas Richman?

Douglas Richman is affiliated with the following schools:

Douglas Richman's Academic­Influence.com Rankings